Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $90.4 million.

  • Arrowhead Pharmaceuticals' Accumulated Expenses rose 43.48% to $90.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.4 million, marking a year-over-year increase of 43.48%. This contributed to the annual value of $90.4 million for FY2025, which is 43.48% up from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Accumulated Expenses is $90.4 million, which was up 39.50% from $64.8 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Accumulated Expenses' 5-year high stood at $90.4 million during Q3 2025, with a 5-year trough of $12.9 million in Q1 2021.
  • For the 3-year period, Arrowhead Pharmaceuticals' Accumulated Expenses averaged around $55.0 million, with its median value being $47.9 million (2024).
  • In the last 5 years, Arrowhead Pharmaceuticals' Accumulated Expenses soared by 234.66% in 2022 and then declined by 15.14% in 2023.
  • Arrowhead Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $18.5 million in 2021, then surged by 160.15% to $48.2 million in 2022, then dropped by 3.26% to $46.6 million in 2023, then increased by 27.46% to $59.4 million in 2024, then spiked by 43.48% to $90.4 million in 2025.
  • Its last three reported values are $90.4 million in Q3 2025, $64.8 million for Q2 2025, and $78.5 million during Q1 2025.